Principles of therapeutics of galanthamine

Drugs of Today

Volumn 33, Issue 4, 1997, Pages 251-257

  Mucke, Hermann A M ^a  

^a Waldheim Pharmazeutika GmbH   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; HUMAN; HYPOTHESIS; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARASYMPATHETIC INNERVATION; REVIEW;

EID: 0030972104     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1997.33.4.425050     Document Type: Review

References (68)

1. Alzheimer, A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiatrie 1907, 64: 146-8.
2. Roth, M., Tomlinson, B.E., Blessed, G. Correlation between scores for dementia and counts of 'senile plaques' in cerebral grey matter of elderly subjects. Nature 1966, 209: 109-10.
3. Roth, M., Tomlinson, B.E., Blessed, G. The relationship between quantitative measures of dementia and of degenerative changes in the cerebral grey matter of elderly subjects. Proc R Soc Med 1967, 60: 254-60.
4. Blessed, G., Tomlinson, B.E., Roth, M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968, 114: 797-811.
5. Deutson, J.A., Lutzky, H. Memory enhancement by anticholinesterase as a function of initial learning. Nature 1967, 210: 742.
6. Gruber, R.P., Stone, G.C., Reed, D.R. Scopolamine-induced anterograde amnesia. Int J Neuropharmacol 1967, 6(3): 187-90.
7. Ilyutchenok, R.Y., Yeliseyeva, A.G. Cholinergic mechanisms of memory: Analysis of the amnesic effect of anticholinergic drugs. Int J Psychobiol 1972, 2(3): 177-92.
8. Crow, T.J., Grove-White, I.G. An analysis of the learning deficit following hyoscine administration to man. Br J Pharmacol 1973, 49: 322-7.
9. Drachman, D.A. et al. Human memory and the cholinergic system: A relationship to aging. Arch Neurol 1974, 30: 113-21.
10. Sunderland, T., Tanot, P.N., Cohen, R.M. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. Arch Gen Psychiatry 1987, 44: 418-26.
11. Nunzio, P., Karen, N., Halpern, G. Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with apolipoprotein E type 4 alleles. Neurochem Res 1996, 20(12): 15-9.
12. Davies, P., Maloney, A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, ii: 1400-5.
13. Perry, E.K., Perry, R.H., Blessed, G. et al. Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977, i: 189.
14. Perry, E.K., Tomlinson, B.E., Blessed, G., Bergmann, K., Gibson, P.H., Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978, 2: 1457-9.
15. Whitehouse, P.J., Price, D.L., Clark, A.W., Royle, J.T., DeLong, M.R. Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981, 10: 122-6.
16. Whitehouse, P.J., Price, D.L, Struble, R.G. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science 1982, 215: 1237-9.
17. Winkler, J., Suhr, S.T., Gage, F.H., Thal, L.J., Fisher, L.J. Essential role of neocortical acetylcholine in spatial memory. Nature 1995, 375: 484-7.
18. Gibson, G.E., Peterson, C., Jenden, D.J. Brain acetylcholine synthesis declines with senescence. Science 1981, 213: 674-6.
19. Slims, N.R., Smith, C.C.T., Davison, A.N., Bowen, D.M., Flack, R.H.A., Snowden, J.S., Neary, D. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer's disease. Lancet 1980, i: 333-5.
20. Yates, C.M., Simpson, J., Maloney, A.F.J., Gordon, A., Reid, A.M. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet 1980, ii: 979.
21. Solitare, G.B., Lamarche, J.B. Alzheimer's disease and senile dementia as seen in mongoloids: Neuropathological observations. Am J Ment Defic 1966, 70(6): 840-8.
22. Owens, D., Dawson, J.C., Losin, S. Alzheimer's disease in Down syndrome. Am J Ment Defic 1971, 75: 606-12.
23. Ellis, W.G., McCulloch, J.R., Corley, D.R.C.L. Presenile dementia in Down's syndrome: Ultrastructural identity with Alzheimer's disease. Neurology 1974, 24: 101-6.
24. Bartus, B.T., Dean, R.L., Beer, B. et al. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982, 217: 408-17.
25. Bartus, B.T., Dean, R.L., Pontecorvo, M.J., Flicker, C. The cholinergic hypothesis: A historical overview, current perspective and future directions. Ann NY Acad Sci 1985, 444: 332-58.
26. Beeri, R., Andres, C., Lev-Lehman, E. et al. Transgenic expression of human acetylcholinesterase induced progressive cognitive deterioration in mice. Curr Biol 1995, 5(9): 1063-71.
27. Perry, E.K. Cortical neurotransmitter chemistry in Alzheimer's disease. In: Pharmacology: The Third Generation of Progress. Melzer, H. (Ed.). Raven Press: New York 1987.
28. Furchgott, R.F., Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288: 373-6.
29. Perry, E.K., Smith, C.J., Court, J.A., Perry, R.H. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm 1990, 2: 149-58.
30. Rosenberg, G.S., Davis, K.L. The use of cholinergic precursors in neuropsychiatric diseases. Am J Clin Nutr 1982, 36(4): 709-20.
31. Whiteley, A., Signoret, J.L., Agid, Y., Lhermitte, F. Action de la choline sur les troubles amnésiques de la maladie d' Alzheimer. Rev Neurol (Paris) 1979, 135: 8-9.
32. Etienne, P., Dastoor, D., Gauthier, S., Ludwick, R., Collier, B. Alzheimer disease: Lack of effect of lecithin treatment for 3 months. Neurology 1981, 31(12): 1552-4.
33. Little, A., Levy, B., Chuaqui-Kidd, P., Hand, D. A double-blind placebo-controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985, 48(8): 736-41.
34. Cacabelos, R., Caamaño, J., Gómez, M.J., Fernández-Novoa, L., Franco-Maside, A., Alvarez, X. Therapeutic effects of CDP-choline in Alzheimer's disease: Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann NY Acad Sci 1996, 777: 399-403.
35. Peters, B.H., Levin, H.S. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol 1979, 6(3): 219-21.
36. Wettstein, A. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol 1983, 13(2): 210-2.
37. Thai, L., Fuld, P.A., Masur, D.M., Sharpless, N.S. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 1983, 13(5): 491-6.
38. Samorajski, T., Uroulis, G.A., Smith, R.C. Piracetam plus lecithin trials in senile dementia of the Alzheimer type. Ann NY Acad Sci 1985, 444: 478-81.
39. Chatellier, G., Lacomblez, T. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: A multicentre trial. Br Med J 1990, 300: 495-9.
40. Sano, M., Bell, K., Cote, T. et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol 1992, 49(11): 1137-41.
41. Hollander, E., Davidson, M., Mohs, R.C. et al. RS-86 in the treatment of Alzheimer's disease: Cognitive and biological effects. Biol Psychiatry 1987, 22: 1067-78.
42. Mouradian, M.H., Mohr, E., Williams, A.J. et al. No response to high-dose muscarinic agonist therapy in Alzheimer's disease. Neurology 1988, 38: 605-8.
43. Raffaele, K.C., Berardi, A., Morris, P.P. et al. Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type. Neuro-Psychopharmacol Biol Psychiatry 1991, 15(5): 643-8.
44. Sramek, J.J., Pharm, D., Hurley, D.J. et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. Clin Pharmacol Ther 1995, 35(8): 6-8.
45. 1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 1995, 57(12): 1183-90.
46. 1 agonists for the treatment of Alzheimer's disease: Novel properties and clinical update. Ann NY Acad Sci 1996, 777: 189-96.
47. Cooper, J.R., Bloom, F.E., Roth, R.H. (Eds.). The Biochemical Basis of Neuropharmacology, Fifth Edition, Oxford University Press: New York 1986.
48. Ravindran, R.S., Cummins, D.F., Pantazis, K.L. Unusual aspects of low levels of pseudocholine esterase in a pregnant patient. Anaesth Analg 1982, 61: 953-7.
49. Giacobini, E., Mori, F., Lai, C-C. The effect of cholinesterase inhibitors on the secretion of APPs from rat brain cortex. Ann NY Acad Sci 1996, 777: 393-8.
50. Lee, R.K.K., Wurtman, R.J., Cox, A.J., Nitsch, R.M. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci USA 1995, 92: 8083-7.
51. Sato, A., Sato, Y. Cholinergic neural regulation of regional cerebral blood flow. Alzheimers Dis Assoc Disord 1995, 9(1): 28-38.
52. Tourtauchaux, R., Jalenques, I., Mestas, D., Maublant, J. Regional cerebral perfusion by Tc-99m HMPAO spect before and after tacrine in patients with Alzheimer's disease. 8th Cong of Assoc Eur Psychiatrists (July 8-12, London) 1996.
53. Leonard, F.M., Daffner, K.R., Dressier, D. et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science 1994, 266: 1051.
54. Schneider, L.S., Farlow, M. Predicting response to cholinesterase inhibitors in Alzheimer's disease: Possible approaches. CNS Drugs 1995, 4(2): 114-24.
55. Ashford, J.W., Soldinger, S., Schaeffer, J., Cochran, L., Jarvik, L.F. Physostigmine and its effects on six patients with dementia. Am J Psychiatry 1981, 138: 829-30.
56. Mohs, R.C., Davis, K.L., Rosenberg, G.S. et al. Studies of cholinergic drug effects on cognition in normal subjects and patients with Alzheimer's disease. In: Brain Neurotransmitters and Receptors in Aging and Age-Related Disorders, Vol. 17. Enna, S.J. et al. (Eds.). Raven Press: New York 1981, 225-30.
57. Christie, J.E., Shering, A., Ferguson, J., Glen, A.L.M. Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer's presenile dementia. Br J Psychiatry 1981, 138: 46-50.
58. Summers, W.K., Viesselman, J.O., Marsh, G.M., Candelora, K. Use of THA in treatment of Alzheimer-like dementia: Pilot study in twelve patients. Biol Psychiatry 1981, 16: 145-53.
59. Davis, K.L., Mohs, R.C., Tinklenberg, J.R. et al. Physostigmine: Improvement of long-term memory processes in normal humans. Science 1978, 201: 272-4.
60. Stern, Y., Sano, M., Mayeux, R. Long-term administration of oral physostigmine in Alzheimer's disease. Ann Neurol 1988, 22: 306-10.
61. Asthana, S., Greig, N.H., Hegedus, L. et al. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995, 58(3): 299-309.
62. Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S., Gracon, S.I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. J Am Med Assoc 1994, 271(13): 985-91.
63. Stevens, D.R., Cotman, C.W. Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons. Neurosci Lett 1987, 79: 301-5.
64. Rogawski, M.H. Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons. Eur J Pharmacol 1987, 142: 169-72.
65. Adem, A., Sukhwinder, S.J., Oreland, L. Tetrahydroaminoacridine inhibits human and rat brain monoamine oxidase. Neurosci Lett 1989, 107: 313-7.
66. Moriearty, P.M. Transdermal delivery of cholinesterase inhibitors: Rationale and therapeutic potential. CNS Drugs 1995, 4(5): 323-34.
67. Proskurnina, N.F., Yakovieva, J. Alkaloids of Galanthus worownii. J Gen Chem USSR 1952, 22: 1899-902.
68. Uyeo, S., Kobayashi, S. Pharm Bull (Jpn) 1953, 139.